Biocryst Pharma Inc (BCRX) Stock Price, Quote & News

Company Profile

BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 919 859 1302

Fax: 919 859 1314

Website: www.biocryst.com

Address:

4505 Emperor Boulevard, Suite 200, Durham, United States

StarshipBlooper May. 15 at 8:52 PM

$BCRX $9.50 on Monday

0 · Reply

WKNDatBERNIES May. 15 at 8:16 PM

$BCRX right at max pain.

1 · Reply

RowdyRoundy May. 15 at 8:15 PM

$BCRX can we get some credit for our nice penetration growth here? I love me some penetration growth! 🍆

0 · Reply

BirdStar May. 15 at 8:04 PM

$BCRX Nicely done, MM's. *Tips hat*

0 · Reply

coleslaugh May. 15 at 7:58 PM

$BCRX let’s see if the 9 dollar calls expire ITM or not

1 · Reply

Fergus20 May. 15 at 7:57 PM

$BCRX back to square one. F all of you losers.

1 · Reply

Fergus20 May. 15 at 7:54 PM

$BCRX ahhh yes, the classic low of the day close.

0 · Reply

Ttubular May. 15 at 7:41 PM

$BCRX bios getting hammered

0 · Reply

Fergus20 May. 15 at 7:38 PM

$BCRX up 1% on the week! HAHAHAHAHAHAHAHA!!!

0 · Reply

Fergus20 May. 15 at 7:34 PM

$BCRX ooof, that’s a backbreaking drop.

0 · Reply

BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026

May 12, 2026, 4:40 PM EDT - 3 days ago

BioCryst Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026

2026-05-07T11:43:06.000Z - 8 days ago

BioCryst price target raised to $28 from $25 at Citizens

2026-05-07T06:49:24.000Z - 8 days ago

BioCryst reports Q1 EPS ($2.98), consensus 11c

May 6, 2026, 8:30 AM EDT - 9 days ago

BioCryst Pharmaceuticals Earnings Call Transcript: Q1 2026

May 6, 2026, 7:00 AM EDT - 9 days ago

BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update

May 5, 2026, 7:00 AM EDT - 10 days ago

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-05-04T11:24:11.000Z - 11 days ago

BioCryst enters navenibart license agreement with Neopharmed Gentili

May 4, 2026, 7:00 AM EDT - 11 days ago

BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema

Apr 28, 2026, 7:00 AM EDT - 17 days ago

BioCryst to Present at Upcoming Investor Conferences

Apr 15, 2026, 7:00 AM EDT - 4 weeks ago

BioCryst to Report First Quarter 2026 Financial Results on May 6

2026-04-07T15:13:58.000Z - 5 weeks ago

BioCryst price target raised to $14 from $13 at RBC Capital

2026-04-06T11:05:55.000Z - 5 weeks ago

BioCryst appoints Sandeep Menon as chief research and development officer

ALNY

Apr 6, 2026, 7:00 AM EDT - 5 weeks ago

BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer

2026-03-04T12:08:31.000Z - 2 months ago

BioCryst reports inducement grants under Nasdaq listing rule

Mar 3, 2026, 9:10 AM EST - 2 months ago

BioCryst Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

2026-03-02T13:53:06.000Z - 2 months ago

BioCryst price target raised to $22 from $21 at Wedbush

Feb 26, 2026, 8:30 AM EST - 2 months ago

BioCryst Pharmaceuticals Earnings Call Transcript: Q4 2025

2026-02-26T12:19:23.000Z - 2 months ago

BioCryst reports Q4 EPS $1.12 vs (13c) last year

Feb 26, 2026, 7:00 AM EST - 2 months ago

BioCryst Reports Full Year 2025 Financial Results and Provides Business Update

2026-02-18T13:16:21.000Z - 3 months ago

BioCryst resumed with an Outperform at Evercore ISI

Feb 17, 2026, 7:00 AM EST - 3 months ago

BioCryst to Present at Upcoming Investor Conference

Feb 11, 2026, 7:00 AM EST - 3 months ago

BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting

2026-02-05T12:17:45.000Z - 3 months ago

BioCryst reports inducement grants under Nasdaq listing rule

Feb 5, 2026, 7:01 AM EST - 3 months ago

BioCryst to Report Fourth Quarter 2025 Financial Results on February 26

2026-01-23T14:05:15.000Z - 4 months ago

BioCryst completes acquisition of Astria Therapeutics

ATXS

Jan 23, 2026, 9:00 AM EST - 4 months ago

BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema

Jan 12, 2026, 1:30 PM EST - 4 months ago

BioCryst Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 7:00 AM EST - 4 months ago

BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range

2026-01-06T12:20:40.000Z - 4 months ago

BioCryst reports inducement grants under Nasdaq listing rule

Jan 6, 2026, 7:00 AM EST - 4 months ago

BioCryst to Present at 44th Annual J.P. Morgan Healthcare Conference

2025-12-15T14:11:34.000Z - 5 months ago

BioCryst price target raised to $32 from $30 at H.C. Wainwright

Dec 12, 2025, 7:06 AM EST - 5 months ago

FDA expands approval of BioCryst's rare disease drug for use in young children

Dec 12, 2025, 7:00 AM EST - 5 months ago

BioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to

Dec 3, 2025, 7:00 AM EST - 5 months ago

BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition

Nov 19, 2025, 12:00 PM EST - 6 months ago

BioCryst Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025

Nov 6, 2025, 8:00 AM EST - 6 months ago

BioCryst Presents New Data at ACAAI Highlighting Burden of HAE on Pediatric Patients and Caregivers and Sustained Reduction of Attacks in Children Treated with One Year of ORLADEYO® (berotralstat)

Nov 3, 2025, 8:30 AM EST - 6 months ago

BioCryst Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 3, 2025, 7:00 AM EST - 6 months ago

BioCryst Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 23, 2025, 7:00 AM EDT - 7 months ago

BioCryst to Present New Pediatric HAE Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting

Oct 20, 2025, 7:00 AM EDT - 7 months ago

BioCryst to Report Third Quarter 2025 Financial Results on November 3

Oct 17, 2025, 3:20 PM EDT - 7 months ago

Astria Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS

ATXS

Oct 14, 2025, 8:00 AM EDT - 7 months ago

BioCryst Pharmaceuticals Transcript: M&A Announcement

Oct 14, 2025, 7:35 AM EDT - 7 months ago

BioCryst to buy Astria Therapeutics in $700 million deal

ATXS

Oct 14, 2025, 7:00 AM EDT - 7 months ago

BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile

ATXS

Oct 1, 2025, 7:00 AM EDT - 8 months ago

BioCryst Completes Sale of European ORLADEYO® (berotralstat) Business

Sep 4, 2025, 9:45 AM EDT - 9 months ago

BioCryst Pharmaceuticals Transcript: Cantor Global Healthcare Conference 2025

Aug 11, 2025, 7:00 AM EDT - 9 months ago

BioCryst Announces Departure of Dr. Helen Thackray

Aug 4, 2025, 8:30 AM EDT - 10 months ago

BioCryst Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 4, 2025, 7:00 AM EDT - 10 months ago

BioCryst Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 31, 2025, 7:00 AM EDT - 10 months ago

BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December

Jul 21, 2025, 7:00 AM EDT - 10 months ago

BioCryst to Report Second Quarter 2025 Financial Results on August 4

Jul 9, 2025, 7:00 AM EDT - 11 months ago

BioCryst to Highlight Patient-focused Research at the 2025 US HAEA National Summit

Jul 7, 2025, 7:00 AM EDT - 11 months ago

BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development

Jun 27, 2025, 8:30 AM EDT - 11 months ago

BioCryst Pharmaceuticals Transcript: M&A Announcement

Jun 27, 2025, 7:00 AM EDT - 11 months ago

BioCryst Announces Sale of European ORLADEYO® (berotralstat) Business to Neopharmed Gentili for up to $264 Million

Jun 16, 2025, 7:00 AM EDT - 11 months ago

BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI

Jun 13, 2025, 7:00 AM EDT - 1 year ago

ORLADEYO® (berotralstat) Approved in Colombia

Jun 9, 2025, 8:40 AM EDT - 1 year ago

BioCryst Pharmaceuticals Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 6, 2025, 7:00 AM EDT - 1 year ago

BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries

Jun 4, 2025, 4:55 PM EDT - 1 year ago

BioCryst Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025

Jun 2, 2025, 7:00 AM EDT - 1 year ago

BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology

May 30, 2025, 7:00 AM EDT - 1 year ago

BioCryst Highlights Real-world Data Showing ORLADEYO® (berotralstat) Consistently Reduces HAE Attacks Across All Ages

May 16, 2025, 7:00 AM EDT - 1 year ago

BioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO® (berotralstat)

May 14, 2025, 1:40 PM EDT - 1 year ago

BioCryst Pharmaceuticals Transcript: Bank of America 2025 Healthcare Conference

May 14, 2025, 7:00 AM EDT - 1 year ago

BioCryst Announces FDA Acceptance of NDA for ORLADEYO® (berotralstat) Oral Granules in Patients with Hereditary Angioedema Aged 2 to 11 Years

May 8, 2025, 9:00 AM EDT - 1 year ago

BioCryst Pharmaceuticals Transcript: The Citizens JMP Life Sciences Conference 2025

May 5, 2025, 8:30 AM EDT - 1 year ago

BioCryst Pharmaceuticals Earnings Call Transcript: Q1 2025

May 5, 2025, 7:00 AM EDT - 1 year ago

BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update

May 1, 2025, 7:00 AM EDT - 1 year ago

BioCryst Appoints Steve Frank to Board of Directors

Apr 21, 2025, 7:00 AM EDT - 1 year ago

BioCryst to Report First Quarter 2025 Financial Results on May 5

Apr 9, 2025, 9:30 AM EDT - 1 year ago

BioCryst Pharmaceuticals Transcript: 24th Annual Needham Virtual Healthcare Conference

Mar 11, 2025, 10:00 AM EDT - 1 year ago

BioCryst Pharmaceuticals Transcript: Barclays 27th Annual Global Healthcare Conference

Mar 5, 2025, 9:10 AM EST - 1 year ago

BioCryst Pharmaceuticals Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 24, 2025, 8:30 AM EST - 1 year ago

BioCryst Pharmaceuticals Earnings Call Transcript: Q4 2024

Feb 24, 2025, 7:00 AM EST - 1 year ago

BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones

Feb 24, 2025, 6:00 AM EST - 1 year ago

BioCryst Announces Positive Results from APeX-P Trial for ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema Aged 2 to

Feb 12, 2025, 7:00 AM EST - 1 year ago

BioCryst Launches ORLADEYO® (berotralstat) in Portugal

Feb 10, 2025, 8:30 AM EST - 1 year ago

BioCryst to Present New ORLADEYO® (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization Joint Congress

Feb 10, 2025, 7:00 AM EST - 1 year ago

BioCryst to Report Fourth Quarter 2024 Financial Results on February 24

Jan 14, 2025, 6:00 PM EST - 1 year ago

BioCryst Pharmaceuticals Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 10, 2025, 7:00 AM EST - 1 year ago

BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)

Jan 7, 2025, 7:00 AM EST - 1 year ago

BioCryst to Present at 43rd Annual J.P. Morgan Healthcare Conference

StarshipBlooper May. 15 at 8:52 PM

$BCRX $9.50 on Monday

0 · Reply

WKNDatBERNIES May. 15 at 8:16 PM

$BCRX right at max pain.

1 · Reply

RowdyRoundy May. 15 at 8:15 PM

$BCRX can we get some credit for our nice penetration growth here? I love me some penetration growth! 🍆

0 · Reply

BirdStar May. 15 at 8:04 PM

$BCRX Nicely done, MM's. *Tips hat*

0 · Reply

coleslaugh May. 15 at 7:58 PM

$BCRX let’s see if the 9 dollar calls expire ITM or not

1 · Reply

Fergus20 May. 15 at 7:57 PM

$BCRX back to square one. F all of you losers.

1 · Reply

Fergus20 May. 15 at 7:54 PM

$BCRX ahhh yes, the classic low of the day close.

0 · Reply

Ttubular May. 15 at 7:41 PM

$BCRX bios getting hammered

0 · Reply

Fergus20 May. 15 at 7:38 PM

$BCRX up 1% on the week! HAHAHAHAHAHAHAHA!!!

0 · Reply

Fergus20 May. 15 at 7:34 PM

$BCRX ooof, that’s a backbreaking drop.

0 · Reply

Fergus20 May. 15 at 7:06 PM

$BCRX WeRe jUsT fIlLiNg ThE gAp!!!

1 · Reply

blue81 May. 15 at 6:30 PM

$BCRX easy 50% until the end of the year also in intellia( ntla ) can earn 100% until end of the year

0 · Reply

Saffier1988 May. 15 at 6:27 PM

$BCRX shitshow !

1 · Reply

StarshipBlooper May. 15 at 6:25 PM

$BCRX $8.99 close

0 · Reply

Fergus20 May. 15 at 5:58 PM

$BCRX squeeze is underway at UPST…Reddit army is behind. Might dump everything here and put it on that.

4 · Reply

joooiink May. 15 at 5:58 PM

$BCRX

0 · Reply

justfkntrade May. 15 at 5:57 PM

$BCRX between personal life shit and now this, fuck man what a horrible day. I really hope this shit just gets sold. Just give me $12 a share at this point I don’t even care I just want to make a little and be out. The opportunity cost of owning this, missing out on insane gains in literally any broad market etf has legitimately altered my life course lol. I hate to bitch and whine but this is just getting so repetitive and ridiculous. We were practically this price when we first got orla approved and now we’ve made hundreds of millions of dollars and gone nowhere.

3 · Reply

Money_Mane May. 15 at 5:42 PM

$BCRX 9-1-1

1 · Reply

clownmarket May. 15 at 5:32 PM

$BCRX $NWBO I assume most people know this but to be clear, NWBO is a scam company which trades on the OTC markets because that is where disclosure requirements and standards are rock bottom They published "positive" phase 3 data in 2022 and four years later, have no approvals anywhere in the world: Northwest Biotherapeutics Northwest Biotherapeutics Reports Positive Top-Line Results From Phase 3 Trial of DCVax®-L for Glioblastoma - Northwest Biotherapeutics https://share.google/v0sk4Jr4ytYF7Co9s The point of the company is to dilute their shareholders (cultists and morons) forever, using the money raised to make related party payments that enrich management

11 · Reply

SCCT2FL May. 15 at 4:34 PM

$BCRX burning the $9 calls for today?

0 · Reply

TornadoChasers May. 15 at 4:27 PM

$IWM $BCRX $RDDT $BULL bullish ones

0 · Reply

Ttubular May. 15 at 4:15 PM

$BCRX right back down we go

1 · Reply

Market Cap	2.44B
Revenue (ttm)	874.84M
Net Income (ttm)	263.86M
EPS (ttm)	N/A
PE Ratio	6.77
Forward PE	28.70
Profit Margin	30.16%
Debt to Equity Ratio	-1.55

Volume	4,575,700
Avg Vol	5,631,690
Day's Range	N/A - N/A
Shares Out	254.16M
Stochastic %K	88%
Beta	0.57
Analysts	Strong Sell
Price Target	$21.40